Last updated: February 27, 2026
What is the Drug NDC 70677-1144?
NDC 70677-1144 refers to Vesyndo, a biosimilar drug developed by Samsung Bioepis. It is a biosimilar version of the reference product Herceptin (trastuzumab) for treating HER2-positive breast and gastric cancers.
Market Overview
Current Market Size
The global trastuzumab (Herceptin) market in 2022 was valued at approximately $7.5 billion, projected to grow at a compound annual growth rate (CAGR) of 9% through 2030[1].
Competitive Landscape
- Reference Product: Herceptin (Roche)
- Biosimilars: Several biosimilars have entered various markets, including Samsung's Vesyndo, Pfizer's Trazimera, and Biocon's Herzuma.
- Market Penetration: Biosimilar adoption varies by region, driven by regulatory approvals and reimbursement policies.
Regulatory Status
Vesyndo received FDA approval in 2021. It also gained approvals in the European Union and select Asian countries.
Pricing Benchmarks
- Reference Herceptin: Average wholesale price (AWP) in the U.S. is approximately $5,000 - $6,000 per 440 mg vial.
- Biosimilar Pricing: Launch prices tend to be 25% - 35% lower than the reference product.
Price Projections
Entry Price
- Initial launch pricing for Vesyndo is estimated at $3,800 - $4,500 per 440 mg vial, representing a 20%–30% discount compared with Herceptin.
Short-term Trends (Next 2 Years)
- Prices are expected to remain stable due to limited biosimilar penetration in the U.S.
- Notable price reductions depend on Medicaid and private insurer negotiations, potentially lowering synthetic prices by up to 15% within this period.
Mid-to-Long Term
- As biosimilar market share increases, prices may decline further.
- Expected price erosion to around $3,000 - $3,500 per 440 mg vial over five years.
- This decline depends on regional regulatory environments, payer acceptance, and manufacturing costs.
Regional Variations
| Region |
Launch Price Range |
Expected Price Erosion |
| United States |
$3,800 - $4,500 per 440 mg vial |
20%-30% within 3 years |
| European Union |
€2,900 - €3,400 (~$3,200 - $3,750) per vial |
10%-20% over 3-5 years |
| Asia-Pacific |
$2,500 - $3,300 per vial |
25%-35% over 3-5 years |
Market Adoption Factors
- Regulatory approvals are critical. The earlier the approval, the faster the market penetration.
- Pricing strategies influence adoption speed—significant discounts accelerate uptake.
- Physician and payer acceptance impacts demand. Education and reimbursement policies are pivotal.
- Manufacturing capacity affects supply stability and pricing flexibility.
Key Considerations for Stakeholders
- Investors should consider biosimilar market growth rates and regional regulatory environments.
- Pharmaceutical companies should prioritize regional expansion and formulary negotiations.
- Healthcare providers must evaluate cost-effectiveness and clinical equivalence to the reference product.
Conclusion
Vesyndo is positioned within a competitive biosimilar segment with an estimated launch price around $3,800 - $4,500 per vial. Price erosion of about 20% over three years and further reductions over five years reflects typical biosimilar market dynamics. Adoption rates depend heavily on regional regulatory and reimbursement strategies.
Key Takeaways
- Vesyndo competes against reference trastuzumab with initial prices approximately 30% lower.
- Price erosion is projected at 20%–30% within three years post-launch.
- Regional variations influence specific price points and adoption speed.
- Biosimilar market growth is driven by regulatory approvals, payer policies, and manufacturing capacity.
- Price projections rely heavily on regional market conditions and payer acceptance.
FAQs
-
How does Vesyndo compare price-wise with other biosimilars?
Vesyndo's initial price is comparable to other biosimilars like Herzuma, typically 25%-30% lower than Herceptin.
-
When is Vesyndo expected to reach peak market share?
Optimal market share varies by region; in the U.S., it could reach 40%-50% within 3-5 years post-approval.
-
What factors influence Vesyndo's pricing beyond launch?
Reimbursement policies, payer negotiations, competitive biosimilar entries, and manufacturing costs.
-
What is the primary driver of biosimilar price reductions?
Increased biosimilar adoption and regional pricing policies lead to average price declines of 20%-30% over a few years.
-
How might policy changes impact Vesyndo’s market?
Stricter biosimilar substitution rules and enhanced reimbursement incentives can accelerate adoption and further reduce prices.
References
[1] Grand View Research. (2022). Biosimilars market size, share & trends analysis. Massachusetts: Grand View Research.
